Jazz Pharmaceuticals plc JAZZ

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.

Our lead marketed products, listed below, are approved in countries around the world to improve patient care.

•Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by FDA in July 2020, and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of IH in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®. Xywav is also approved in Canada for the treatment of cataplexy in patients with narcolepsy.

Last close 214.00 2026-10-23
Market cap $13.89B 2026-06-30 share count
52-week range 128.80 - 266.38

Valuation FY2025 figures against the last close

P/S3.3x
P/E—
P/FCF10.7x
EV/EBITDA—
Dividend yield—
Diluted EPS-5.84

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • All other
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 3.8B (89.8%) 90% United States Europe, FY2025: 341.1M (8.0%) 8% Europe All other, FY2025: 94.9M (2.2%) FY2024 United States, FY2024: 3.7B (90.0%) 90% Europe, FY2024: 312.7M (7.7%) 8% All other, FY2024: 96.1M (2.4%) FY2023 United States, FY2023: 3.5B (91.0%) 91% Europe, FY2023: 269.2M (7.0%) 7% All other, FY2023: 75M (2.0%)
Region FY2025FY2024FY2023
United States $3.83B $3.66B $3.49B
Europe $341.1M $312.7M $269.2M
All other $94.9M $96.1M $75.0M

As the company reported it, from the “Revenues - Schedule of Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B
R&D ——————$299.7M$226.6M$198.4M$162.3M
SG&A $1.81B$1.39B$1.34B$1.42B$1.45B$854.2M$736.9M$683.5M$544.2M$502.9M
Total operating expenses $4.70B$3.35B$3.26B$3.72B$2.92B$1.99B$1.63B$1.28B$1.09B$896.3M
Operating income -$430.2M$716.6M$578.6M-$65.5M$170.3M$378.1M$532.4M$614.8M$528.8M$591.7M
Pre-tax income -$627.9M$470.4M$297.9M-$372.8M-$112.8M$275.1M$454.3M$529.5M$441.1M$532.4M
Income tax $272.4M$91.4M$119.9M$158.6M$216.1M$33.5M$73.2M$80.2M$47.7M$135.2M
Net income -$356.1M$560.1M$414.8M-$224.1M-$329.7M$238.6M$523.4M$447.1M$487.8M$396.8M
EPS, basic -5.849.066.55-3.58-5.524.289.227.458.136.56
EPS, diluted -5.848.656.10-3.58-5.524.229.097.307.966.41
Shares, diluted (wtd. avg.) 61.0M66.0M72.1M62.5M59.7M56.5M57.5M61.2M61.3M61.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.39B$2.41B$1.51B$881.5M$591.4M$1.06B$637.3M$309.6M$386.0M$366.0M
Receivables $830.7M$716.8M$705.8M$651.5M$563.4M$396.5M$356.0M$263.8M$224.1M$234.2M
Inventory $417.0M$480.4M$597.0M$714.1M$1.07B$95.4M$78.6M$53.0M$43.2M$34.1M
Total current assets $4.17B$4.63B$3.44B$2.61B$2.61B$2.84B$1.63B$1.23B$968.3M$748.1M
Property, plant and equipment —————$127.9M$131.5M$200.4M$170.1M$107.5M
Goodwill $1.83B$1.72B$1.75B$1.69B$1.83B$958.3M$920.0M$927.6M$947.5M$893.8M
Other intangibles $4.43B$4.76B$5.42B$5.79B$7.15B$2.20B$2.44B$2.73B$2.98B$3.01B
Total assets $11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B
Accounts payable $122.1M$77.9M$102.8M$90.8M$100.3M$26.9M$45.7M$40.6M$24.4M$22.4M
Short-term debt $1.03B$31.0M$605.0M$31.0M$31.0M$246.3M$33.4M$33.4M$40.6M$36.1M
Total current liabilities $2.24B$1.04B$1.54B$933.2M$809.3M$653.7M$364.5M$345.5M$293.9M$257.4M
Long-term debt $4.33B$6.08B$5.11B$5.69B$6.02B$1.85B$1.57B$1.56B$1.54B$1.99B
Retained earnings $646.2M$1.13B$878.7M$733.6M$830.2M$1.16B$1.07B$841.0M$918.0M$528.9M
Total equity $4.32B$4.09B$3.74B$3.09B$3.97B$3.66B$3.11B$2.76B$2.71B$1.88B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.36B$1.40B$1.09B$1.27B$778.5M$899.6M$776.4M$798.9M$693.1M$592.4M
Depreciation and amortisation $41.6M$32.8M$30.4M$30.3M$26.7M$18.7M$15.3M$15.2M$13.1M$11.8M
Stock-based compensation $291.1M$248.0M$226.8M$222.0M$189.0M$121.0M$110.6M$102.4M$106.9M$98.8M
Capital expenditure $58.8M$38.1M$24.0M$29.0M$27.6M$15.0M$40.1M$20.4M$28.9M$9.7M
Investing cash flow -$1.51B-$508.2M-$163.1M-$446.2M-$5.21B-$1.01B-$155.3M-$394.5M-$268.9M-$1.75B
Financing cash flow -$873.4M$20.5M-$305.3M-$529.5M$3.97B$528.1M-$293.7M-$479.1M-$409.1M$541.0M
Buybacks $125.0M$311.4M$269.8M$54.0K$0$146.5M$301.4M$523.7M$98.8M$278.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001232524-26-000029.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B 0 2B 4B 6B Revenue, FY2016: 1.5B Net income, FY2016: 396.8M Revenue, FY2017: 1.6B Net income, FY2017: 487.8M Revenue, FY2018: 1.9B Net income, FY2018: 447.1M Revenue, FY2019: 2.2B Net income, FY2019: 523.4M Revenue, FY2020: 2.4B Net income, FY2020: 238.6M Revenue, FY2021: 3.1B Net income, FY2021: -329.7M Revenue, FY2022: 3.7B Net income, FY2022: -224.1M Revenue, FY2023: 3.8B Net income, FY2023: 414.8M Revenue, FY2024: 4.1B Net income, FY2024: 560.1M Revenue, FY2025: 4.3B Net income, FY2025: -356.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.49B $1.62B $1.89B $2.16B $2.36B $3.09B $3.66B $3.83B $4.07B $4.27B
Gross profit — — — — — — — — — —
Net income $396.8M $487.8M $447.1M $523.4M $238.6M -$329.7M -$224.1M $414.8M $560.1M -$356.1M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%